Japan­ese biotech pitch­ing iP­SC-de­rived med for the heart gains $26M; An­dreessen Horowitz leads $4.1M seed fund­ing for AI up­start

→ A long­time re­searcher in car­diac re­gen­er­a­tive med­i­cine has closed a $26 mil­lion Se­ries B to ad­vance his de­vel­op­ment of iP­SC-de­rived car­diomy­ocytes as a treat­ment for heart fail­ure. Kei­ichi Fuku­da con­vinced a num­ber of new in­vestors, in­clud­ing SBI In­vest­ment, JMDC, Gene Tech­no Sci­ence, Nis­say Cap­i­tal and SM­BC Cap­i­tal, to join Astel­las Ven­ture Man­age­ment in back­ing Tokyo-based Heart­seed. The biotech ex­pects to launch its own Phase I/II for the lead drug in HFrEF late next year, while sup­port­ing an­oth­er tri­al for di­lat­ed car­diomy­opa­thy ini­ti­at­ed by Keio Uni­ver­si­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.